Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF. It combines immune checkpoint inhibition with anti-angiogenic activity in a single molecule.
Ivonescimab
Ivonescimab is the world’s first-in-class PD-1/VEGF bispecific immunotherapy drug with a combined mechanism of tumor immunotherapy and anti-angiogenesis. Ivonescimab has been approved by China’s, National Medical Products Administration (NMPA) for the treatment of EGFR mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) in patients who have progressed after EGFR-TKI treatment.
Strength:
100 mg(10mL)/bottle
Dosage:
20 mg/kg intravenously every 3 weeks (Q3W) as monotherapy or in combination with chemotherapy.
Adverse reactions:
Common side effects include fatigue, skin rash, and mild gastrointestinal symptoms such as nausea and diarrhea.
One of the more serious side effects is immune-related adverse events, which occur when the immune system becomes overactive and starts attacking normal tissues. This can lead to conditions such as pneumonitis, colitis, hepatitis and endocrinopathies.
Storage:
Short-term storage: Stable at 2°C to 8°C for short durations (up to a few months).
Long-term storage: Store at -20°C to -80°C for long-term stability.
One of the more serious side effects is immune-related adverse events, which occur when the immune system becomes overactive and starts attacking normal tissues.
This can lead to conditions such as
- Pneumonitis (inflammation of the lungs)
- Colitis (inflammation of the colon)
- Hepatitis (inflammation of the liver)
- Endocrinopathies (disorders of the endocrine glands).
If left untreated, these conditions can be life-threatening. Therefore, patients should promptly report any unusual symptoms to their healthcare provider.
Contraindications for Ivonescimab use include a history of severe allergic reactions to monoclonal antibodies or components of the drug formulation.
It is also important for women who are pregnant or planning to become pregnant to avoid this medication, as it could potentially harm the developing fetus.
Additionally, patients with pre-existing autoimmune disorders should use Ivonescimab with caution, as it could exacerbate their condition
FAQ
What is its mechanism of action?
Ivonescimab binds both:
- PD-1 on T cells, restoring antitumor immune activity.
- VEGF, inhibiting tumor angiogenesis.
This dual blockade is designed to enhance antitumor efficacy beyond PD-1 inhibition alone.
How is Ivonescimab administered?
- Intravenous infusion.
- Usually administered every 3 weeks.
- Patients should be monitored during infusion and for infusion-related reactions.
What monitoring is recommended?
Before and during treatment:
- CBC
- Liver function tests
- Renal function
- Urine protein assessment
- Blood pressure monitoring
- Assessment for immune-related toxicities.
What is the cost of Ivonescimab in India?
The cost of Ivonescimab in India depends on factors such as dosage, availability, import requirements and supplier pricing. As Ivonescimab is generally accessed through special procurement channels, the final price may vary. For the latest Ivonescimab price in India, contact 24/7QualityMeds at +91 9967979080 for current pricing, availability and import assistance.
How to buy Ivonescimab online in India?
To buy Ivonescimab online in India, patients typically need a valid prescription from a licensed healthcare provider. Once the prescription is available, authorized suppliers such as 24/7QualityMeds can assist with availability checks, procurement, and import support. Contact us to buy Ivonescimab in India and receive guidance throughout the process.




